Cambridge precision medicine software startup Genospace is helping launch broad-scale precision medicine initiative in Newfoundland and Labrador.
In tandem with Canadian startup Sequence Bioinformatics, Genospace is plans to collect and analyze the genotypic and phenotypic data from 100,000 participants. This project is similar to the U.S., England and several other countries that are launching their own precision medicine efforts to track population health.
“The Newfoundland and Labrador population is a unique resource for genetic investigation of complex diseases,” Genospace CEO Mick Correll said in a statement. “The province’s collaboration with Sequence Bio takes a community-based approach to apply the latest genomic technologies to advance data-driven precision medicine.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Genospace has built out a secure IT structure to manage genomic and phenotypic information, and an analytics platform that lets the government, academia and industry collaborate.
